A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Kelleher, Anthony D; Puls, Rebekah; Bebbington, Mark; Boyle, David B; Ffrench, Rosemary A; Kent, Stephen J; Kippax, Susan; Purcell, Damian F J; Thomson, Scott; Wand, Handan; Cooper, David A.; Emery, Sean; Munier, Mee Ling; Coupar, Barbara E H; Fielden, Robert; Jaramillo, Angel B; Keoshkerian, Elizabeth; Law, Matthew G; Ramsay, Alistair; Ramshaw, Ian; Satchell, Claudette; Van Bockel, David; Saunders, John B

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Date

2006

Authors

Kelleher, Anthony D

Puls, Rebekah

Bebbington, Mark

Boyle, David B

Ffrench, Rosemary A

Kent, Stephen J

Kippax, Susan

Purcell, Damian F J

Thomson, Scott

Wand, Handan

Publisher

Lippincott Williams & Wilkins

Abstract

An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.